All In MedTech

FDA Clearance Tracker · P150035-S013

Aveir™ Leadless System (Dual-Chamber)

A PMA supplement is a change to a device that already has premarket approval, such as a new indication, a design change or a manufacturing change.

Last checked: Nov 20, 2026Latest source record: Sep 25, 2024 (this decision)Source: openFDAMethods & limitations

PMA supplement

Decided

Sep 25, 2024

Approved

Time to decision

89 days

Received Jun 28, 2024. Calendar days, including time FDA spent waiting on the applicant.

Pathway

PMA supplement

Normal 180 Day Track

Device class

Class III

The decision

FDA number
P150035-S013
Device name
Aveir™ Leadless System (Dual-Chamber)
Applicant location
Sylmar, CA
Received
Jun 28, 2024
Decided
Sep 25, 2024
Decision
Approved
Supplement type
Normal 180 Day Track
Reason for supplement
Change Design/Components/Specifications/Material
Original approval
P150035

Device type

Device class
Class III
Regulation
21 CFR 870.3610

Every decision under product code PNJ

FDA's approval statement

As written in FDA's record.

approval for a new dual-chamber functional operating mode (AAI(R)+VVI) for the Aveir DR Leadless Pacing System

Source documents

Other decisions for ABBOTT MEDICAL

Matched on the applicant name as FDA recorded it. A company that files under several names will have more.

Company page

7 more FDA decisions with a free account

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.